Additionally, actual biological consequences have been suggested previously in humans for the reduced enzymatic activity of the A2 glycosyltransferase or A 1 glycosyltransferase, most clearly in relation to circulating levels of von Willebrand factor (vWF) and the risk of venous thromboembolism (VTE). The gene discussed is VWF; the disease is venous thromboembolism.